The higher the clinical need and the prevalence, the higher the effort from scientists around the world in trying to solve a problem. Pancreatic ductal adenocarcinoma (PDAC) remains one of the highest unsolved clinical needs today. It is a devastating disease with an unfavorable outcome and is projected to become the second deadliest cancer by 2030. Currently the overall 5-year survival rate is less than 10% despite all efforts. But new therapies are being pushed forward every month, the rhythm of innovation here is extraordinary.
All big unsolved clinical needs may be a good investment opportunity. Here’s a conceptual map (by no means complete) with some of the leading-edge alternatives and targets that are being moved forward. A map just to navigate the landscape and avoid getting lost amid all the different categories and approaches.
You can find all my quick notes at #quick_notes_LP
